SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting
PRAGUE, Czech Republic, May 11, 2021 (GLOBE NEWSWIRE) --
SOTIO, a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting. The presentation focuses on potentially predictive biomarker data from a phase 2 study of SOTIO’s dendritic cell vaccine (DCVAC/OvCa) combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma after primary debulking surgery.
SOTIO’s DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique. SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs.
Title: Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial
Poster Number: 5521
Session: Poster Discussion Session, Gynecologic Cancer
Presenting Author: Lukas Rob, MD, PhD, University Hospital Kralovske Vinohrady (Prague, Czech Republic)
Date / Time: (Virtual) Friday, June 4th, from 9:00 AM – 10:00 AM EST
Conference Registration Link: https://login.asco.org/login/user?target=https:%2F%2Frah.asco.org%2Fsso%2Flogin.aspx%3FmeetingID%3D273
A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes, and a recorded oral presentation focused on the data will be hosted on the online ASCO Media Library.
About SOV01 clinical trial:
SOV01 is a randomized, open-label, three-arm multicenter Phase II clinical trial evaluating DCVAC/OvCa in combination with first-line standard chemotherapy in women with newly diagnosed epithelial ovarian cancer following radical debulking surgery.
|Company contact:||Media contact:|
|Richard Kapsa||Michael Tattory|
|Head of Communication||LifeSci Communications|
|T: (+420) 224 174 448||T: +1 (646) 751-4362|
|M: (+420) 603 280 email@example.com|
SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies, CAR T platform and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com.
SOTIO is a registered trademark of SOTIO a.s. in selected countries.
Upcoming Life Sciences Events
- October 2021
- BIO-Europe® 2021
- Online: AusBiotech 2021 & Australia Biotech Invest & Partnering
- November 2021
- Pharma-Biotech Product & Company Valuation with Dr. P Frei